감염증 체외진단 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Infectious Disease In-vitro Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

US $ 4,995 ￦ 7,088,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,352,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,055,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

세계 감염증 체외진단 시장 규모는 2024년 445억 달러로 2024-2031년 예측 기간 동안 4.7%의 CAGR로 확대되어 2031년에는 612억 달러에 달할 것으로 예상됩니다.

감염증 체외진단 시장은 박테리아, 바이러스, 곰팡이, 기생충 등 병원균에 의한 감염을 감지하는 데 사용되는 진단 검사를 말합니다. 이러한 진단 검사는 감염성 질환의 조기 발견, 관리 및 치료에 필수적입니다. 이 시장을 주도하는 요인은 전 세계 감염병 발병률 증가, 진단 기술의 기술 발전, 신속하고 정확한 진단 도구에 대한 수요 증가, 특히 세계 팬데믹의 영향을 받고 있습니다. 시장에는 분자진단, 면역측정, 미생물 검사 등 다양한 분야가 포함됩니다.

전 세계 감염증 체외진단 시장의 성장에는 특히 개발도상국의 감염성 질환 유병률 증가, 의료 인프라의 성장 등 여러 요인이 기여하고 있습니다. 조기 진단에 대한 인식이 높아지고 감염성 질환에 대한 현장진단(POCT)에 대한 수요가 증가하면서 시장 성장을 더욱 촉진하고 있습니다. 또한, COVID-19, 결핵, HIV, 말라리아 등의 질병 발생 빈도가 증가함에 따라 정확하고 빠른 진단 도구에 대한 수요가 증가하고 있습니다. 또한, 분자진단 및 차세대 염기서열 분석(NGS)의 기술 발전은 시장을 발전시킬 것으로 예상됩니다.

감염증 체외진단 시장은 특히 감염성 질환의 증가로 인해 더 나은 진단 도구에 대한 수요가 증가하고 있는 신흥국에서 큰 비즈니스 기회를 제공하고 있으며, PCR 기반 기술과 CRISPR을 포함한 분자진단의 발전은 기술 혁신과 확장을 위한 새로운 기회를 제공하고 있습니다. 또한, 맞춤형 의료의 증가와 멀티플렉스 검사 플랫폼의 개발은 시장 진입 기업에게 성장의 길을 열어줄 것입니다. 또한 진단 기업과 의료 서비스 제공자 간의 협업이 증가함에 따라 시장 확대의 새로운 기회가 열릴 것으로 예상됩니다.

이 보고서는 전 세계 감염증 체외진단 시장을 조사하여 제품 유형별, 기술별, 용도별, 최종사용자별, 지역별 동향, 시장 진입 기업 프로파일 등을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
• 거시경제 요인
• COVID-19의 영향 분석
• 예측요인 - 관련성과 영향

제3장 부가가치 인사이트

제4장 세계의 감염증 체외진단 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

• 주요 하이라이트
• 시장 규모(10억 달러) 분석과 예측
• 세계의 감염증 체외진단 시장 전망 : 제품 유형별
• 시장 매력 분석 : 제품 유형별
• 세계의 감염증 체외진단 시장 전망 : 기술별
• 시장 매력 분석 : 기술별
• 세계의 감염증 체외진단 시장 전망 : 용도별
• 시장 매력 분석 : 용도별
• 세계의 감염증 체외진단 시장 전망 : 최종사용자별
• 시장 매력 분석 : 최종사용자별

제5장 세계의 감염증 체외진단 시장 전망 : 지역별

• 주요 하이라이트
• 과거 시장 규모(10억 달러) 분석, 지역별, 2019-2023년
• 현재 시장 규모(10억 달러) 분석과 예측, 지역별, 2024-2031년
• 시장 매력 분석 : 지역별

제6장 북미의 감염증 체외진단 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제7장 유럽의 감염증 체외진단 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제8장 동아시아의 감염증 체외진단 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제9장 남아시아 및 오세아니아의 감염증 체외진단 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제10장 라틴아메리카의 감염증 체외진단 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제11장 중동 및 아프리카의 감염증 체외진단 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제12장 경쟁 구도

• 시장 점유율 분석, 2023년
• 시장 구조
• 기업 개요(상세 - 개요, 재무, 전략, 최근의 동향)
  • QIAGEN
  • Becton, Dickinson and Company
  • bioMerieux SA
  • F. Hoffmann-La Roche, Ltd.
  • Hologic, Inc.(Gen Probe)
  • Abbott
  • Quidel Corporation
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • OraSure Technologies, Inc.

제13장 부록

ksm

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Infectious Disease In-vitro Diagnostics (IVD) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Infectious Disease In-vitro Diagnostics Market Size (2024E): US$ 44.5 Bn
• Projected Market Value (2031F): US$ 61.2 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 4.7%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

The Infectious Disease In-vitro Diagnostics market refers to diagnostic tests used for detecting infections caused by pathogens such as bacteria, viruses, fungi, and parasites. These diagnostic tests are essential in the early detection, management, and treatment of infectious diseases. The market is driven by rising global infectious disease prevalence, technological advancements in diagnostic technologies, and an increasing need for rapid and accurate diagnostic tools, especially in the wake of global pandemics. The market encompasses various segments, including molecular diagnostics, immunoassays, and microbiology testing.

Market Growth Drivers:

Several factors are contributing to the growth of the global Infectious Disease IVD market, including the rising incidence of infectious diseases, especially in developing regions, and growing healthcare infrastructure. Increasing awareness about early diagnosis and the growing demand for point-of-care testing (POCT) for infectious diseases are further propelling market growth. The need for accurate and rapid diagnostic tools is also rising due to the increasing frequency of outbreaks of diseases such as COVID-19, tuberculosis, HIV, and malaria. Additionally, technological advancements in molecular diagnostics and next-generation sequencing (NGS) are expected to drive the market forward.

Market Restraints:

Despite its growth potential, the Infectious Disease IVD market faces challenges such as high costs associated with advanced diagnostic tests, particularly in low-income regions. Regulatory hurdles in some countries, along with the need for extensive validation and certification of diagnostic products, may also limit market expansion. Moreover, the lack of awareness in remote areas regarding the availability and benefits of in-vitro diagnostics poses a barrier to the widespread adoption of diagnostic tools.

Market Opportunities:

The Infectious Disease IVD market presents significant opportunities, particularly in emerging economies, where the demand for better diagnostic tools is growing due to the rising burden of infectious diseases. Advancements in molecular diagnostics, including PCR-based technologies and CRISPR, offer new opportunities for innovation and expansion. Further, the increasing trend toward personalized medicine and the development of multiplex testing platforms provide growth avenues for market players. Additionally, the rise in collaborations between diagnostic companies and healthcare providers is expected to open new opportunities for market expansion.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the global Infectious Disease IVD market?
• Which diagnostic technologies and testing platforms are leading the market in terms of demand and revenue?
• How are advancements in molecular diagnostics and PCR technologies influencing the Infectious Disease IVD market?
• Who are the leading players in the Infectious Disease IVD market, and what strategies are they employing to maintain their market positions?
• What are the emerging trends and future prospects in the global Infectious Disease IVD market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Infectious Disease IVD market, such as Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers, are focusing on enhancing their product portfolios, including rapid diagnostics and molecular testing platforms. These companies are investing in innovative technologies such as real-time PCR, next-generation sequencing (NGS), and point-of-care testing solutions. Collaborations with healthcare providers, research institutions, and public health organizations are critical to expanding market reach. Moreover, focusing on regulatory compliance, product differentiation, and technological advancements will help companies maintain a competitive edge and capitalize on the growing demand for efficient and accurate infectious disease diagnostics.

Key Companies Profiled:

• QIAGEN
• Becton, Dickinson and Company
• bioMerieux SA
• F. Hoffmann-La Roche, Ltd.
• Hologic, Inc. (Gen Probe)
• Abbott
• Quidel Corporation
• Siemens Healthineers AG
• Bio-Rad Laboratories, Inc.
• Danaher
• OraSure Technologies, Inc.

Infectious Disease In-vitro Diagnostics Industry Segmentation

By Product Type

• Instruments
• Reagents
• Software and Services

By Technology

• Immunoassay
• Molecular Diagnostics
• Microbiology

By Application

• MRSA
• Clostridium Difficile
• Respiratory Virus
• TB and Drug-resistant TB
• Gonorrhea
• HPV
• HIV
• Hepatitis C
• Hepatitis B
• COVID-19

By End User

• Point-of-care
• Central Laboratories

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Infectious Disease In-Vitro Diagnostics Market Snapshot, 2024 - 2031
• 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Adoption Analysis
• 3.3. Value Chain Analysis
• 3.4. Key Deals and Mergers
• 3.5. Parent Market Analysis
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024 - 2031
• 4.3. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Product Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019 - 2023
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 4.3.3.1. Instruments
    • 4.3.3.2. Reagents
    • 4.3.3.3. Software and Services
• 4.4. Market Attractiveness Analysis: Product Type
• 4.5. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Technology
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019 - 2023
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 4.5.3.1. Immunoassay
    • 4.5.3.2. Molecular Diagnostics
    • 4.5.3.3. Microbiology
    • 4.5.3.4. Others
• 4.6. Market Attractiveness Analysis: Technology
• 4.7. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Application
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019 - 2023
  • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 4.7.3.1. MRSA
    • 4.7.3.2. Clostridium Difficile
    • 4.7.3.3. Respiratory Virus
    • 4.7.3.4. TB and Drug-resistant TB
    • 4.7.3.5. Gonorrhea
    • 4.7.3.6. HPV
    • 4.7.3.7. HIV
    • 4.7.3.8. Hepatitis C
    • 4.7.3.9. Hepatitis B
    • 4.7.3.10. COVID-19
    • 4.7.3.11. Others
• 4.8. Market Attractiveness Analysis: Application
• 4.9. Global Infectious Disease In-Vitro Diagnostics Market Outlook: End User
  • 4.9.1. Introduction / Key Findings
  • 4.9.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2023
  • 4.9.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 4.9.3.1. Point-of-care
    • 4.9.3.2. Central Laboratories
    • 4.9.3.3. Others
• 4.10. Market Attractiveness Analysis: End User

5. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2023
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024 - 2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 6.2.1. By Country
  • 6.2.2. By Product Type
  • 6.2.3. By Technology
  • 6.2.4. By Application
  • 6.2.5. By End User
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
  • 6.4.1. Instruments
  • 6.4.2. Reagents
  • 6.4.3. Software and Services
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
  • 6.5.1. Immunoassay
  • 6.5.2. Molecular Diagnostics
  • 6.5.3. Microbiology
  • 6.5.4. Others
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
  • 6.6.1. MRSA
  • 6.6.2. Clostridium Difficile
  • 6.6.3. Respiratory Virus
  • 6.6.4. TB and Drug-resistant TB
  • 6.6.5. Gonorrhea
  • 6.6.6. HPV
  • 6.6.7. HIV
  • 6.6.8. Hepatitis C
  • 6.6.9. Hepatitis B
  • 6.6.10. COVID-19
  • 6.6.11. Others
• 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
  • 6.7.1. Point-of-care
  • 6.7.2. Central Laboratories
  • 6.7.3. Others
• 6.8. Market Attractiveness Analysis

7. Europe Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 7.2.1. By Country
  • 7.2.2. By Product Type
  • 7.2.3. By Technology
  • 7.2.4. By Application
  • 7.2.5. By End User
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
  • 7.4.1. Instruments
  • 7.4.2. Reagents
  • 7.4.3. Software and Services
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
  • 7.5.1. Immunoassay
  • 7.5.2. Molecular Diagnostics
  • 7.5.3. Microbiology
  • 7.5.4. Others
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
  • 7.6.1. MRSA
  • 7.6.2. Clostridium Difficile
  • 7.6.3. Respiratory Virus
  • 7.6.4. TB and Drug-resistant TB
  • 7.6.5. Gonorrhea
  • 7.6.6. HPV
  • 7.6.7. HIV
  • 7.6.8. Hepatitis C
  • 7.6.9. Hepatitis B
  • 7.6.10. COVID-19
  • 7.6.11. Others
• 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
  • 7.7.1. Point-of-care
  • 7.7.2. Central Laboratories
  • 7.7.3. Others
• 7.8. Market Attractiveness Analysis

8. East Asia Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 8.2.1. By Country
  • 8.2.2. By Product Type
  • 8.2.3. By Technology
  • 8.2.4. By Application
  • 8.2.5. By End User
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
  • 8.4.1. Instruments
  • 8.4.2. Reagents
  • 8.4.3. Software and Services
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
  • 8.5.1. Immunoassay
  • 8.5.2. Molecular Diagnostics
  • 8.5.3. Microbiology
  • 8.5.4. Others
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
  • 8.6.1. MRSA
  • 8.6.2. Clostridium Difficile
  • 8.6.3. Respiratory Virus
  • 8.6.4. TB and Drug-resistant TB
  • 8.6.5. Gonorrhea
  • 8.6.6. HPV
  • 8.6.7. HIV
  • 8.6.8. Hepatitis C
  • 8.6.9. Hepatitis B
  • 8.6.10. COVID-19
  • 8.6.11. Others
• 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
  • 8.7.1. Point-of-care
  • 8.7.2. Central Laboratories
  • 8.7.3. Others
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 9.2.1. By Country
  • 9.2.2. By Product Type
  • 9.2.3. By Technology
  • 9.2.4. By Application
  • 9.2.5. By End User
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
  • 9.4.1. Instruments
  • 9.4.2. Reagents
  • 9.4.3. Software and Services
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
  • 9.5.1. Immunoassay
  • 9.5.2. Molecular Diagnostics
  • 9.5.3. Microbiology
  • 9.5.4. Others
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
  • 9.6.1. MRSA
  • 9.6.2. Clostridium Difficile
  • 9.6.3. Respiratory Virus
  • 9.6.4. TB and Drug-resistant TB
  • 9.6.5. Gonorrhea
  • 9.6.6. HPV
  • 9.6.7. HIV
  • 9.6.8. Hepatitis C
  • 9.6.9. Hepatitis B
  • 9.6.10. COVID-19
  • 9.6.11. Others
• 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
  • 9.7.1. Point-of-care
  • 9.7.2. Central Laboratories
  • 9.7.3. Others
• 9.8. Market Attractiveness Analysis

10. Latin America Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 10.2.1. By Country
  • 10.2.2. By Product Type
  • 10.2.3. By Technology
  • 10.2.4. By Application
  • 10.2.5. By End User
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
  • 10.4.1. Instruments
  • 10.4.2. Reagents
  • 10.4.3. Software and Services
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
  • 10.5.1. Immunoassay
  • 10.5.2. Molecular Diagnostics
  • 10.5.3. Microbiology
  • 10.5.4. Others
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
  • 10.6.1. MRSA
  • 10.6.2. Clostridium Difficile
  • 10.6.3. Respiratory Virus
  • 10.6.4. TB and Drug-resistant TB
  • 10.6.5. Gonorrhea
  • 10.6.6. HPV
  • 10.6.7. HIV
  • 10.6.8. Hepatitis C
  • 10.6.9. Hepatitis B
  • 10.6.10. COVID-19
  • 10.6.11. Others
• 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
  • 10.7.1. Point-of-care
  • 10.7.2. Central Laboratories
  • 10.7.3. Others
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 11.2.1. By Country
  • 11.2.2. By Product Type
  • 11.2.3. By Technology
  • 11.2.4. By Application
  • 11.2.5. By End User
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
  • 11.4.1. Instruments
  • 11.4.2. Reagents
  • 11.4.3. Software and Services
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
  • 11.5.1. Immunoassay
  • 11.5.2. Molecular Diagnostics
  • 11.5.3. Microbiology
  • 11.5.4. Others
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
  • 11.6.1. MRSA
  • 11.6.2. Clostridium Difficile
  • 11.6.3. Respiratory Virus
  • 11.6.4. TB and Drug-resistant TB
  • 11.6.5. Gonorrhea
  • 11.6.6. HPV
  • 11.6.7. HIV
  • 11.6.8. Hepatitis C
  • 11.6.9. Hepatitis B
  • 11.6.10. COVID-19
  • 11.6.11. Others
• 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
  • 11.7.1. Point-of-care
  • 11.7.2. Central Laboratories
  • 11.7.3. Others
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. QIAGEN
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Becton, Dickinson and Company
  • 12.3.3. bioMerieux SA
  • 12.3.4. F. Hoffmann-La Roche, Ltd.
  • 12.3.5. Hologic, Inc. (Gen Probe)
  • 12.3.6. Abbott
  • 12.3.7. Quidel Corporation
  • 12.3.8. Siemens Healthineers AG
  • 12.3.9. Bio-Rad Laboratories, Inc.
  • 12.3.10. Danaher
  • 12.3.11. OraSure Technologies, Inc.

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료